Search Results

T2 Biosystems, Inc. announced that the U.S. Department of Health and Human Services and the Steven & Alexandra Cohen Foundation have selected T2 Biosystems as a Phase 2 winner in the LymeX Diagnostics Prize, a prize competition to accelerate the development of Lyme disease diagnostics.

Applied DNA Sciences, Inc. (NASDAQ:APDN) (“Applied DNA” or the “Company”), a leader in PCR-based DNA technologies, today announced that the New York State Department of Health (“NYSDOH”) approved the Company’s TR8™ PGx (“TR8") pharmacogenomic (PGx) testing service.

Imagine Pharma, a biotech company focused on advancing the commercialization of its novel IMG-1 polypeptide in Oral Delivery, Therapeutics, and Regenerative Medicine, announced that the West Virginia University Health System, which operates under the brand WVU Medicine, has awarded a contract to the Company to provide human clinical islet isolation services for patients undergoing a total pancreatectomy and autologous islet cell transplant.

Vertex has filed a complaint against the Department of Health and Human Services, seeking to make its fertility preservation program available to federally insured patients needing Casgevy treatment.

Amneal Pharmaceuticals, Inc. announced that a delegation of senior members of the U.S. Department of Health and Human Services and U.S. Food and Drug Administration together with local government officials recently visited the Company’s manufacturing facility in Matoda, India.

The Department of Health – Abu Dhabi, the regulator of the healthcare sector in the Emirate, signed a Memorandum of Understanding with Pfizer Gulf FZ LLC, a global pharmaceutical company during BIO 2024 International Convention.

The Department of Health and Human Services’ Office of the Inspector General found that bluebird bio’s fertility support program for its gene therapies could potentially violate federal anti-kickback statutes.

The Department of Health – Abu Dhabi, the regulator of the healthcare sector in the Emirate, signed a Memorandum of Understanding with Roche Pharmaceuticals Middle East during Abu Dhabi Global Healthcare Week.

The Department of Health – Abu Dhabi, the regulator of the healthcare sector in the Emirate, signed a Memorandum of Understanding with AstraZeneca during BIO International Convention 2024 to establish a world-class Rare Diseases Centre of Excellence in Abu Dhabi.

Antengene Corporation Limited announced that South Korea’s National Health Insurance Service has approved the reimbursement of XPOVIO® for the treatment of adult patients with relapsed or refractory multiple myeloma.